Valuation: Neuland Laboratories Limited

Market Cap 281B 2.91B 2.59B 2.42B 2.19B 4.14B 4.17B 29.07B 11.31B 143B 10.94B 10.7B 461B P/E 2027 *
58.7x
P/E 2028 * 45x
Enterprise Value 283B 2.94B 2.61B 2.44B 2.21B 4.18B 4.21B 29.34B 11.41B 145B 11.04B 10.8B 465B EV / Sales 2027 *
11.6x
EV / Sales 2028 * 9.66x
Free-Float
62.26%
Yield 2027 *
0.11%
Yield 2028 * 0.14%
1 day+0.14%
1 week+2.17%
Current month+2.60%
1 month-3.33%
3 months+15.63%
6 months+76.18%
Current year+44.35%
1 week 20,715
Extreme 20715
21,975
1 month 20,715
Extreme 20715
24,225
Current year 11,500
Extreme 11500
24,225
1 year 11,500
Extreme 11500
24,225
3 years 3,611.1
Extreme 3611.1
24,225
5 years 967
Extreme 967
24,225
10 years 245.75
Extreme 245.75
24,225
Manager TitleAgeSince
Chief Executive Officer 47 2026-03-31
Director of Finance/CFO - 2022-11-22
Chief Tech/Sci/R&D Officer - 2023-02-28
Director TitleAgeSince
Director/Board Member 50 2001-12-31
Chairman 82 1984-01-06
Director/Board Member 47 2007-02-28
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+2.17% - - 2.91B
+1.52%-2.14%+37.19%+105.11% 1,019B
+1.35%-4.74%+35.46%+61.69% 610B
+0.28%+1.32%+15.89%+79.95% 470B
+1.73%-5.30%+59.19%+36.08% 344B
+0.26%+0.14%+21.29%+40.99% 336B
+0.60%-3.09%+10.76%+32.59% 266B
+1.65%-3.78%-6.03%+9.29% 241B
-0.07%-5.07%+36.74%+50.36% 218B
-0.28%-4.91%+26.65%+92.47% 179B
Average +0.66%-3.63%+26.35%+56.50% 409.2B
Weighted average by Cap. +0.94%-3.51%+29.51%+67.04%

Financials

2027 *2028 *
Net sales 24.35B 253M 224M 210M 190M 359M 362M 2.52B 980M 12.42B 948M 928M 39.94B 29.18B 303M 269M 251M 228M 430M 434M 3.02B 1.17B 14.89B 1.14B 1.11B 47.86B
Net income 4.8B 49.78M 44.19M 41.35M 37.48M 70.78M 71.29M 497M 193M 2.45B 187M 183M 7.87B 6.26B 64.99M 57.69M 53.99M 48.93M 92.41M 93.08M 648M 252M 3.2B 244M 239M 10.27B
Net Debt 2.56B 26.57M 23.59M 22.07M 20.01M 37.78M 38.05M 265M 103M 1.31B 99.73M 97.59M 4.2B 979M 10.16M 9.02M 8.44M 7.65M 14.45M 14.55M 101M 39.42M 500M 38.13M 37.32M 1.61B
Projected Income Statement - Annual - Neuland Laboratories Limited
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
26-10-06 ₹21,905.00 +0.14% 61,813
26-10-05 ₹21,875.00 +1.72% 62,813
26-10-01 ₹21,505.00 +0.73% 70,377
26-09-30 ₹21,350.00 -0.12% 51,295
26-09-29 ₹21,375.00 -0.30% 83,910
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Neuland Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21,891.65INR
Average target price
24,334.75INR
Spread / Average Target
+11.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Neuland Laboratories Limited